Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients

Table 2

Level of serum cytokines and chemokines (pg/mL) in MS patients at baseline and follow-up period.

Cytokine	−2 weeks		7 weeks		10 weeks		18 weeks
	Median	IQR	Median	IQR	Median	IQR	Median	IQR
TNF-	5.7	4.2–8.7	6.1	2.6–15.9	4.2	3.4–9.3	9.2	6.6–14.5
IFN-	155	107–226	155	58–332	100	33–203	171	91–360
CCL4	337	311–378	293	208–429	337	229–441	278	216–394
CCL2	97	78–123	90	57–142	82	49.3–111	86	64–98
G-CSF	9.5	5.7–23.2	10.2	7.2–14.6	9.0	5.6–18.6	12	8–32
IL-1	2.5	2.4–4.0	3.6	2.9–6.4	2.9	2.3–3.2	3.2	3.1–3.7
IL-2	1.4	0.4–22.4	0.4	0.4–1.6	0.7	0.4–10.7	0.5	0.4–10
IL-4	1.6	1.2–3.7	1.5	1.3–2.8	1.6	1.0–2.2	1.6	1.3–2.6
IL-5	5.6	3.6–7.8	4.7	3.2–9.3	4.9	3.0–7.2	6.4	3.4–9.2
IL-6	8.6	5.6–14.3	9.6	3.4–14.8	8.7	5.1–16.6	8.5	5.7–13.3
IL-7	15	12–23	12.1	5.8–17.2	12.5	9.4–13.6	11.5	9.2–13.6
IL-8	25	16–39	23	17–146	19	16–35	20	16–30
IL-10	14	7–25	12.4	6.3–15.2	9.5	6.3–16.8	12	7–19
IL-12	23	17–67	18	13–28	17	11–60	32	16–57
IL-13	4.4	2.7–6.8	3.2	2.7–7.0	3.7	2.9–4.8	4.9	3.6–6.0
IL-17	9.3	4.6–19.7	10.4	3.6–18.8	11.3	4.6–17.1	11	3.9–14.1
GM-CSF		Under detection limit